Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations
Sodium-glucose cotransporter 2 (SGLT2) inhibitors were originally developed as glucose-lowering agents for type 2 diabetes mellitus, but accumulating evidence has demonstrated their broad cardiovascular and cardiorenal benefits beyond glycemic control. In particular, empagliflozin and dapagliflozin...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2026-06-01
|
| Serier: | Frontiers in Cardiovascular Medicine |
| Fag: | |
| Online adgang: | https://www.frontiersin.org/articles/10.3389/fcvm.2026.1776906/full |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|